Ligand Pharmaceuticals Incorporated (LGND) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ligand Pharmaceuticals Incorporated  (NASDAQ: LGND)

Ligand Pharmaceuticals Incorporated's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Ligand Pharmaceuticals Incorporated in the third quarter 2026?
Ligand Pharmaceuticals Incorporated achieved a return on average equity (ROE) of 5.22 % in its third quarter 2026, which is below Ligand Pharmaceuticals Incorporated's average return on equity, which stands at 27.34%.

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 54 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2026 from 860 to 866.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Equity Change 1.22 % 16.78 % 25.37 % 22.49 % -
Y / Y Net Income Change - 900.78 % - - -
Net Income (TTM) in Millions 51 197 154 124 49
Return On Equity (TTM) 5.22 % 20.06 % 16.19 % 13.86 % 5.71 %
LGND's Total Ranking # 866 # 860 # 875 # 1608 #
Equity (TTM) in Millions 962 968 997 1,017 950
Seq. Equity Change -0.59 % -2.99 % -1.96 % 7.06 % 14.68 %
Seq. Net Income Change - - - -61.81 % 2319.5 %

Back to LGND Management Effectiveness >> LGND's 5 Years Annual ROE >> Compare LGND ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 55
Sector # 166
Overall # 866

Return On Equity Statistics
High Average Low
232.76 %
27.34 %
-16.36 %
(Sep 30 2015)   (Mar 31 2025)





LGND Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 1,017 830 701 597 821
Y / Y Equity Change 22.49 % 18.48 % 17.31 % -27.24 % 15.73 %
Net Income in Millions 124 -4 52 -33 57
Y / Y Net Income Change - - - - -
Return On Equity 12.23 % -0.49 % 7.44 % -5.58 % 6.96 %

Back to LGND Management Effectiveness >> LGND's 5 Years Annual ROE >> Compare LGND ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 12.23 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
LGND's' Return on Equity at Yahoo Finance
LGND's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for LGND's Competitors
Subscribers only: Roe for Ligand Pharmaceuticals Incorporated's Suppliers
Subscribers only: Return On Equity for LGND's Customers




Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector ROE
Bio rad Laboratories Inc   14.07 %
Boston Scientific Corporation  13.75 %
Inspire Medical Systems inc   12.49 %
Haemonetics Corporation  12.07 %
Labcorp Holdings Inc   11.55 %
Henry Schein Inc   11.29 %
Medinotec Inc   10.97 %
Tactile Systems Technology Inc   10.73 %
Penumbra Inc  10.44 %
Teleflex Incorporated  9.67 %
Merit Medical Systems Inc  9.65 %
U S Physical Therapy Inc  9.48 %
Abbott Laboratories  9.00 %
Pacific Health Care Organization Inc  8.10 %
Incyte Corporation  7.08 %
Conmed Corporation  7.07 %
Teva Pharmaceutical Industries Limited  6.37 %
Integer Holdings Corporation  6.02 %
Avantor Inc   5.96 %
Ligand Pharmaceuticals Incorporated  5.22 %
Lifestance Health Group Inc   4.82 %
Jazz Pharmaceuticals Plc  4.62 %
Pfizer Inc  4.62 %
Innovage Holding Corp   4.52 %
Icu Medical Inc  2.81 %
Biogen Inc   1.86 %
Integra Lifesciences Holdings Corp  1.24 %

Date modified: 2026-10-31T17:28:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.